Isolation of three new meroterpenoids and seven known compounds from Albatrellus yasudae and their Aβ-aggregation inhibitory activity

Bioorg Med Chem Lett. 2020 Jan 15;30(2):126808. doi: 10.1016/j.bmcl.2019.126808. Epub 2019 Nov 21.

Abstract

Alzheimer's disease is a serious neurologic disorder that cannot be cured completely. In this study, we targeted compounds that inhibit amyloid-beta (Aβ) aggregation, based on the amyloid cascade hypothesis. Ten compounds (1-10) were isolated from CHCl3 extracts of the mushroom Albatrellus yasudae using Aβ-aggregation inhibitory activity-guided separation. The structures of these compounds were elucidated from 1D and 2D NMR and MS spectral data. Compounds 1-3 were novel, whereas 4-10 were identified as the known compounds grifolin, grifolic acid, neogrifolin, confluentin, 2-hydroxyneogrifolin, daurichromenic acid, and a cerebroside derivative. Compounds 1-10 were tested for Aβ-aggregation inhibitory activity. Compounds 1, 3, 5, 6, 8, and 9 have potential as Aβ-aggregation inhibitory activity.

Keywords: Albatrellus yasudae; Alzheimer’s disease (AD); Amyloid β aggregation; Meroterpenoid; Mushroom; Thioflavin T.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / metabolism
  • Basidiomycota / chemistry*
  • Basidiomycota / metabolism
  • Humans
  • Magnetic Resonance Spectroscopy
  • Mass Spectrometry
  • Molecular Conformation
  • Resorcinols / chemistry*
  • Resorcinols / metabolism
  • Terpenes / chemistry*
  • Terpenes / metabolism

Substances

  • 4-farnesyl-5-methylresorcinol
  • Amyloid beta-Peptides
  • Resorcinols
  • Terpenes